CMV specific T-cell product (Charite Universitatsmedizin Berlin)

N/A

Report date: 2025/03/18 18:13:41

Base Information

Drug NameCMV specific T-cell product (Charite Universitatsmedizin Berlin)
Drug Alias Namesecond generation CMV-specific T cell product (Charite Universitatsmedizin Berlin)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCytomegalovirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCharité – Universitätsmedizin Berlin
China Registration ClassN/A

Develop Information

Active CompaniesCharité – Universitätsmedizin Berlin
Inactive CompaniesN/A
Active IndicationsCytomegalovirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A